Introduction
============

*Streptomyces* species are known for the most prolific antibiotic producers and have provided a large number of clinical drugs during past decades. However, discovery of natural product (NP) drugs from these talented bacteria has suffered a blow after the Golden Age of NP discovery in 1950s--1960s, that is severely influenced by high-throughput screening of synthetic libraries and the low efficiency of traditional top-down screening strategies ([@B33]). Recently, great advances in next-generation sequencing technologies and computational resources reacquaint microbial genomes and are regarded as a huge reservoir of untapped NP biosynthetic gene clusters (BGCs; [@B46]; [@B55]; [@B30]); moreover, a vast majority of uncultured microorganisms in environments provide limitless possibilities for NP drugs discovery ([@B3]; [@B29]). For *Streptomyces*, the most gifted bacteria are supposed to possess 20--50 BGCs in a single genome, that greatly exceed the identified compounds ([@B5]; [@B2]). Nevertheless, most of BGCs are silent or poorly expressed in native hosts under conventional laboratory culture conditions. To activate these cryptic BGCs, high-efficient approaches for genome editing and BGC engineering garner widespread attention and become a rapidly advancing field for NP drugs discovery ([@B20]; [@B46]; [@B6]; [@B23]; [@B34]; [@B44]; [@B64]).

Compared with other model organisms, like *Escherichia coli* and *Saccharomyces cerevisiae*, *Streptomyces* strains show poverty in genetic manipulation and most are recalcitrant for genome editing. In *Streptomyces*, recombinase-mediated homologous recombination has been commonly used for genome editing; however, the related protocols are often laborious and time-consuming ([@B18]; [@B31]; [@B12]; [@B34]). Until recently, application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated (Cas) system, especially the CRISPR/Cas9 system, has greatly facilitated high-efficiency genome editing ([@B27]; [@B6]). Likewise, CRISPR/Cas9-based genome editing approaches have greatly accelerated insights into *Streptomyces* derived NP drugs. In this mini review, we summarize the recent developments and challenges of CRISPR/Cas9-based approaches for editing BGCs of *Streptomyces*; moreover, cloning and assembly of intact BGCs for heterologous expression are also emphasized.

Crispr/Cas9 Advances the Genome Editing
=======================================

CRISPR/Cas system functions as adaptive immune system in numerous bacteria and archaea, of which RNAs harboring "spacer" sequence from previously exposed bacteriophages help Cas proteins recognize and cleave the specific exogenous DNA ([@B4]; [@B17]; [@B19]). Since CRISPR/Cas system exhibits higher specificity and accuracy on sequence targeting, it has become excellent choice for precision genome editing ([@B27]). CRISPR/Cas9, a type II CRISPR/Cas system, originally employs CRISPR RNA (crRNA) and *trans*-activating crRNA (tracrRNA) to form crRNA-tracrRNA duplex and then assists Cas9 nuclease to recognize and cleave target DNA harboring trinucleotide protospacer adjacent motif (PAM) and a 5' end of 20 nucleotides complementary to the spacers ([@B9]; [@B27]; [@B20]; [@B42]). System reprogramming that fuses crRNA and tracrRNA into a synthetic single guide RNA (sgRNA) greatly facilitates preparation of transcripts and significantly promotes the application of CRISPR/Cas9 system ([@B27]; [@B20]). Reprogrammed CRISPR/Cas9 system has since been successfully used in a variety of organisms, including *S. cerevisiae* ([@B10]), *Drosophila melanogaster* ([@B16]), *Caenorhabditis elegans* ([@B14]), plants ([@B26]), and human embryos ([@B1]).

*In Vivo* Strategies for Genome Editing in *Streptomyces*
=========================================================

*Streptomyces* are of utmost importance for novel NP drugs discovery, of which the investigating process relies heavily on high-efficiency genome editing. In *Streptomyces*, classic genome editing commonly achieves through homologous recombination with a suicide or temperature-sensitive or self-replicative plasmid, and requires intensive and time-consuming screening process. The application of CRISPR/Cas9 system for genome editing in *Streptomyces* started in 2015, and since then related approaches have been tremendously developed. As shown in **Table [1](#T1){ref-type="table"}**, diversified approaches are widely used to edit or refactor BGCs for NP drugs discovery and characterization.

###### 

Application of CRISPR/Cas9 strategies for genome/BGC editing in *Streptomyces* and some rare actinomycetes.

                                Methods                                            BGCs                                                                            Function                 Host (original/surrogate)     References
  ----------------------------- -------------------------------------------------- ------------------------------------------------------------------------------- ------------------------ ----------------------------- ---------------
  *In vivo* editing strategy    pCRISPomyces system                                Phosphinothricin tripeptide                                                     Deletion                 *S. viridochromogenes*        [@B7]
                                                                                   Macrolactam, Lanthipeptide                                                      Deletion                 *S. albus*                    
                                                                                   Red, Actinorhodin (ACT)                                                         Deletion                 *S. lividans*                 [@B7]; [@B53]
                                                                                   Eumelanin                                                                       Deletion                 *Actinoplanes* sp. SE50/110   [@B56]
                                                                                   Formicamycins                                                                   Deletion                 *S. formicae*                 [@B43]
                                                                                   Oxytetracycline                                                                 Site mutation/Deletion   *S. rimosus*                  [@B24]
                                pKCcas9dO system                                   ACT, Red, Ca2 + -dependent antibiotic (CDA)                                     Deletion/Site mutation   *S. coelicolor*               [@B22]
                                                                                   BGC13                                                                           Replacement              *S. pristinaespiralis*        [@B35]
                                                                                   Cryptic type I polyketide, Red, CDA                                             Replacement              *S. coelicolor*               
                                pCRISPR-Cas9 system                                ACT                                                                             Deletion                 *S. coelicolor*               [@B51]
                                                                                   Sceliphrolactam                                                                 Deletion                 *Streptomyces* sp. SD85       [@B38]
                                                                                   Dynemicin                                                                       Deletion                 *Micromonospora chersina*     [@B8]
                                pCRISPR-dCas9 system                               ACT                                                                             Reversible regulation    *S. coelicolor*               [@B51]
                                CRISPR/Cas9-CodA(sm) combined system               ACT                                                                             Deletion                 *S. coelicolor*               [@B58]
                                CRISPR--Cas9 knock-in strategy                     Indigoidine                                                                     Promoter insertion       *S. albus*                    [@B61]
                                                                                   ACT, Red                                                                        Promoter insertion       *S. lividans*                 
                                                                                   Alteramide A, Polycyclic tetramate macrolactam, FR-900098, type I polyketides   Promoter insertion       *S. roseosporus*              
                                                                                   type III polyketide                                                             Promoter insertion       *S. venezuelae*               
                                                                                   Pentangular type II polyketide                                                  Promoter insertion       *S. viridochromogenes*        
  Direct cloning                CATCH                                              Jadomycin                                                                       Cloning                  *S. venezuelae*               [@B25]
                                                                                   Chlortetracycline                                                               Cloning                  *S. aureofaciens*             
  BGC refactoring in yeast      mCRISTAR                                           Tetarimycin, Lazarimide, AB1210                                                 Promoter refactoring     *S. albus*                    [@B28]
  *In vitro* editing strategy   ICE                                                RK-682                                                                          Deletion/Insertion       *S. lividans*                 [@B37]
                                                                                   Holomycin                                                                       Deletion                 *S. albus*                    
                                                                                   Tü 3010                                                                         Deletion                 *S. avermitilis*              [@B50]
                                CRISPR/Cas9 system combined with Gibson assembly   Pristinamycin II                                                                Vector refactoring       *S. pristinaespiralis*        [@B35]
                                                                                   Chloramphenicol                                                                 Vector refactoring       *S. coelicolor*               
                                                                                                                                                                                                                          

[@B7] first introduced CRISPR/Cas9 system for genome editing in *Streptomyces.* The pCRISPomyces-2 system equips a codon-modified Cas9 nuclease driven by a strong promoter, a sgRNA expression cassette, and a 2 kb homology repair template (HRT). It first specifically generates a double-strand break (DSB) at target site by Cas9 nuclease under the guidance of sgRNA harboring a custom-designed spacer, and then repairs the resulting chromosome break by homology-dependent repair (HDR) system in the presence of HRT and introduces chromosomal deletions ranging from 20 bp to 31 kb with an efficiency ranging from 70 to 100% (**Figure [1A](#F1){ref-type="fig"}**). Multiplex genome editing may be achieved by equipping multiplex sgRNA cassettes and corresponding repairing templates in a pCRISPomyces system, and excision of 31 kb BGC of undecylprodigiosin (Red) in *Streptomyces lividans* 66 has thus successfully obtained.

![Editing of BGCs based on CRISPR/Cas9 strategies. **(A)** HDR-mediated editing in *Streptomyces*. Gene deletion, point mutation, or promoter substitution can be performed, respectively, when the repairing template carries corresponding deletion, point mutation, or promoter replacement. Multiplex loci editing can be achieved by equipping multiplex sgRNA cassettes and corresponding HRTs. **(B)** NHEJ-mediated editing in *Streptomyces*. Small sized deletion, insertion, or substitution (mostly 1--3 bp) close to the target site can be achieved by using a reconstituted NHEJ system that co-expressing the *scaligD* in *S. coelicolor*. **(C)** mCRISTAR for BGC refactoring in yeast. **(D)** *In vitro* editing of BGC by ICE or SRISPR/Cas9 coupling Gibson assembly.](fmicb-09-01660-g001){#F1}

Slightly afterward, three different groups successively applied CRISPR/Cas9 system in *Streptomyces* for diverse applications. The pKCcas9dO system by Lu group similarly revealed high editing efficiency of CRISPR/Cas9 system in *Streptomyces coelicolor* M145 for single gene/BGC deletion, as well as multiplex genes/BGCs deletions ([@B22]). Besides, a point mutation editing strategy that CRISPR/Cas9 cleaves chromosome DNA at specific site guided by synthetic sgRNA, and then the HDR in *S. coelicolor* helps repair DSB in assistance of HRT with designed point mutation (AAG of 262--264 nucleotides in *rpsL* was changed to GAA), has performed to convert Lys88 to Glu in *rpsL* (**Figure [1A](#F1){ref-type="fig"}**). [@B51] have thoroughly investigated editing efficiency when repairing Cas9-generated site-specific DSBs by non-homologous end joining (NHEJ) system in *S. coelicolor* A3(2). It revealed an incomplete NHEJ system in *S. coelicolor* that lacking a core component LigD, and led to randomly sized deletions around target site. Reconstitution of this defective NHEJ system by complementing *Streptomyces carneus* derived ScaligD has increased editing efficiency up to 77% and qualified the mutations to 1--3 bp deletion/insertion/substitution in most cases (**Figure [1B](#F1){ref-type="fig"}**). Moreover, high precision genome editing efficiency near 100% achieved when supplying the HRT. In the study, CRISPRi using a catalytically inactive Cas9 nuclease (dCas9) has also been developed, to target promoter region or open reading frame of *actIORF1* for reversible regulation of actinorhodin production in *S. colicolor*. In the same year, Sun group developed an extraordinary CRISPR/Cas9-CodA(sm) combined system, using CodA(sm), the D314A mutant of cytosine deaminase to convert 5-fluorocytosine to toxic 5-fluorouracil, as an efficient counter-selection approach to select for progenies lost recombinant plasmid, which greatly accelerates screening process ([@B58]). Besides, a most significant feature that differs from above three systems is application of a segregationally unstable *sti^-^* pIJ101-derived shuttle vector. The behavior of self-replication with high copy number of about 50 per chromosome of this deliver vector can produce large amounts of single-strand plasmid DNA and plenty of template DNAs, resulting in dramatically high efficiency of double cross-over recombination and frequency of target mutant ([@B58]). All the above reports facilitate rapid progress for genome editing in *Streptomyces*, since CRISPR/Cas9 helps select against wild-type sequence in the presence of HRTs. CRISPR/Cas9 system also enables activation of cryptic BGCs in *Streptomyces*. Zhao group utilized CRISPR/Cas9-mediated knock-in strategy for efficient and precise insertion of constitutive promoters upstream of main biosynthetic operons or pathway-specific activators, and triggered production of novel NPs of different classes in multiple *Streptomyces* species (**Figure [1A](#F1){ref-type="fig"}**; [@B61]).

To date, CRISPR/Cas9 system has been applied for genome editing in *Streptomyces* for 3 years, the high specificity and efficiency made it the most attractive technology in that field. Its application has now extended to many non-model *Streptomyces* strains, like *Streptomyces formicae* from the African fungus-growing plant-ant *Tetraponera penzigi* ([@B43]), *Streptomyces rimosus* with distinctive chromosome terminal and core regions ([@B24]), *Streptomyces* sp. SD85 from tropical mangrove sediments ([@B38]), and some rare actinomycetes like *Actinoplanes* sp.SE50/110 ([@B56]) and *Micromonospora chersina* ([@B8]). However, *in vivo* application of this fascinating technology in *Streptomyces* is confined to the strains are genetically tractable, missing out on a vast amount of precious BGC resources from genetically intractable strains or yet uncultured strains. In that case, acquiring and refactoring of intact BGCs for heterologous expression in a genetically tractable surrogate host could be alternatively considered.

Crispr/Cas9-Mediated Bgcs Cloning and Refactoring for Heterologous Expression
=============================================================================

Cloning of Large-Sized BGCs
---------------------------

A variety of cryptic BGC awakening approaches, like pathway-specific/global regulator manipulation, promoter refactoring, and ribosome engineering, have been used for NPs discovery in *Streptomyces*. However, most require genetic manipulation of native strains thus are constrained in genetically intractable strains or BGCs from environmental DNA (eDNA; [@B46]; [@B54]; [@B60]). Strategies for heterologous expression of BGCs in a genetically manipulatable host can perfectly circumvent above bottleneck, but cloning and editing of large-sized BGCs (sometimes over 100 kb) remain challenging. For cloning large-sized DNAs, classic strategies generally utilize randomly digested genomic libraries; however, the screening process is always laborious and it is arduous for packaging intact BGCs over 100 kb in a single vector. Previous precision cloning strategies often utilize restriction enzymes (REs) to release target BGCs that subsequently acquired by coupling diverse DNA capturing strategies. Linear--linear homologous recombination (LLHR) uses RecE/T mediated homologous recombination for direct capture of REs generated genome segments and is widely used for direct cloning of NP BGCs from *Streptomyces* ([@B15]; [@B40]). Gibson assembly coupling REs cleavage is also used for capturing BGCs, and accordingly, the conglobatin cluster has target cloned by Leadlay group ([@B63]). Transformation-associated recombination (TAR) cloning uses homologous recombination in *S. cerevisiae* to capture REs generated BGC segments, and has employed for cloning BGCs of taromycin A ([@B57]), alterochromide ([@B45]), and thiotetronates ([@B49]). However, these REs-dependent approaches are severely constrained for broader application since appropriate RE cutting sites do not regularly exist close to BGC terminals. CRISPR/Cas9 system perfectly addresses the limitation, that target cleaves the DNA guided by a synthetic sgRNA, allowing target cloning of large-sized BGCs. [@B52] tentatively applied CRISPR/Cas9 system as REs *in vitro* to linearize a large vector (22 kb) and subsequently seamlessly assembled with a small DNA using Gibson assembly ([@B52]). For precision acquiring large-sized DNAs harboring NP BGCs, [@B25] developed Cas9-assisted targeting of chromosome segments (CATCH), which allows target cloning of intact BGCs up to 100 kb that cleaved by CRISPR/Cas9 at specific sites guided by custom-designed sgRNAs and subsequent target captured by Gibson assembly ([@B25]). Simultaneously, [@B32] combined CRISPR/Cas9 with TAR cloning that employs homologous recombination in yeast to target capture CRISPR/Cas9 released chromosomal segments and dramatically accelerated capture efficiency of TAR cloning up to 32% ([@B32]). Soon after, CRISPR/Cas9 system coupling TAR cloning was further applied to construct even megabase-sized DNA segments. [@B62] developed Cas9-facilitated homologous recombination assembly (CasHRA), which co-introduces large circular DNAs into *S. cerevisiae* and release the target DNA segments by CRISPR/Cas9 for subsequent assembly by homologous recombination. It provides an alternative for assembly of large-sized BGCs over 100 kb, using DNAs obtained from cosmid libraries of *Streptomyces* or eDNA. However, it involves assembly steps and tends to be time-consuming.

CRISPR/Cas9-Mediated Editing of BGCs
------------------------------------

Acquiring of intact BGCs of interest is the first step to heterologously investigate the novel NP drugs. Editing of acquired BGCs is generally required for successful heterologous expression. Routine strategies for BGCs editing are always constrained by difficulty of handling large-sized DNAs, and are always laborious. λ-Red recombination mediated PCR-targeting has often used for editing BGC by creating gene replacements/deletions; however, residues like antibiotic selection markers or FRT sequence remain at editing sites, and unintended recombination may raise from repetitive sequences of such modular PKS or NRPS genes ([@B18]; [@B57]). λ-Red recombination also enables promoter refactoring or domains/modules exchange for characterization of NPs biosynthesis ([@B41]; [@B11]). Recently, a more facile promoter refactoring approach based on homologous recombination in *S. cerevisiae* has been developed by Brady group, that enables multiplex promoter refactoring in a single TAR reaction ([@B39]). Based on this, production of eDNA-derived indolotryptoline antiproliferative agents, lazarimides A and B, was activated. Nevertheless, the refactoring rate is relatively low. Homologous recombination in yeast could be greatly improved if specific DSBs are introduced at recombination sites ([@B47]; [@B48]; [@B32]). Accordingly, Brady group developed multiplexed-CRISPR-TAR (mCRISTAR) approach, which introduces CRISPR/Cas9 system to specifically create DSBs across target recombination sites ([@B28]). With mCRISTAR, multiplex CRISPR/Cas9 generated operon fragments can be reassembled with synthetic promoter cassettes by homologous recombination, and are capable of achieving four promoters exchange simultaneously in a single round using one auxotrophic marker selection, with efficiency up to 80% (**Figure [1C](#F1){ref-type="fig"}**). General applicability of mCRISTAR has been validated by applying to activate three different cryptic BGCs coding for tetarimycin, lazarimide, and AB1210, indicating a powerful and promising technology for discovery of novel NP drugs from cryptic BGCs resource.

In contrast to the above *in vivo* strategies for BGC editing based on homologous recombination in *E. coli* or *S. cerevisiae*, Sun group developed a new *in vitro* CRISPR/Cas9-mediated editing (ICE) system for high-efficient BGCs editing ([@B37]). ICE system allows a complete *in vitro* operating process with normal molecular operations, which cleaves BGCs at specific sites guided by synthetic sgRNAs and ligates the blunt ends that are repaired by T4 polymerase, to create gene in-frame deletion/replacement/insertion mutations (**Figure [1D](#F1){ref-type="fig"}**). With ICE system, BGCs of tetronate RK-682 and dithiolopyrrolone holomycin were readily edited ([@B37]), especially for Tü 3010, a particular thiotetronate antibiotic, various gene in-frame deletions were rapidly constructed and accordingly deciphered biosynthesis of this exceptional thiotetronate structure ([@B50]). Soon afterward Lu group utilized a similar *in vitro* approach that coupling CRISPR/Cas9 system with Gibson assembly to refactor the bacterial artificial chromosome vector harboring BGC of pristinamycin II for following multiplexed site-specific genome engineering in *Streptomyces* (**Figure [1D](#F1){ref-type="fig"}**; [@B35]). The above two examples indicate that *in vitro* application of CRISPR/Cas9 could be of wide applicability for BGCs editing, especially coupling the subsequent heterologous expression of BGCs for NP drugs discovery, characterization, and engineering. Nevertheless, optimization of *in vitro* strategies for multiplex loci refactoring of BGCs is of great necessity, and coupling of CRISPR/Cas9 system with Gibson assembly may preliminarily address the problem.

Conclusion
==========

In conclusion, CRISPR/Cas9 system has proved to be a powerful technology for genome editing or BGC refactoring due to the outstanding features, like higher sequence specificity, artificial guided targeting, and high editing efficiency. Its applications of genome editing specialized for *Streptomyces* are still relatively narrower in range, especially for the strains little studied. Thus, more efficient and convenient CRISP/Cas tools are of urgent requirement. For instance, diversified CRISPR/Cas systems like Cpf1 ([@B59]; [@B13]; [@B36]), the newly identified class 2 type V CRISPR/Cas protein, xCRISPR/Cas9 ([@B21]), the most recently evolved CRISPR/Cas9 system with broad PAM compatibility, and even the CRISPR/Cas systems from *Streptomyces* ([@B6]) could be introduced for diverse applications in *Streptomyces*, to advance the researches on NP drugs and open a new era for NP drugs discovery.
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